Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.12 -4.15%

-$0.41 today

Market cap
$186.68M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.23M

Average 0.26M

Returns on capital

Cartesian Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

103.2%

avg 179.4%

ROIC

-28.4%

avg -54.0%

ROA

-44.0%

avg -48.8%

Analysis

ROE is currently the strongest return metric at 103.2% versus its period average of 179.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Peter G. Traber

Head of R&DUSD 2.76M71——

Carsten Brunn

President, Chief Executive Officer & Chairman of the BoardUSD 1.04M55323.53K1.10%

Blaine T. Davis

Chief Financial OfficerUSD 693.35K52——

Emily English

Chief Operating OfficerUSD 589.81K4671.00K0.24%

Matthew Bartholomae

General Counsel & Secretary————

June Seymour

Chief Accounting Officer—48——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$205,797.00

Sells

3

$258,671.22

Net Transaction Value

−$52,874.22

Net selling

Most Active

Brunn Carsten

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jan 6, 26

Brunn Carsten

Direct

Sell$162.1K
Jan 6, 26

Miljkovic Milos

Direct

Sell$24.4K
Jan 6, 26

Davis Blaine

Direct

Sell$72.2K
Dec 4, 25

BARABE TIMOTHY C

Direct

Buy$205.8K

Summary

Insiders reported 1 buys worth $205,797.00 and 3 sells worth $258,671.22 over the last 12 months. That adds up to net selling of $52,874.22. Brunn Carsten was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-70.7%
+142.5% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -70.7% over three years. Forward estimates point to Revenue at +142.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Cartesian Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RNAC's management, answered from reported figures.

Who manages RNAC?

Cartesian Therapeutics, Inc. (RNAC) lists 6 active executives. The top listed executive is Carsten Brunn, President, Chief Executive Officer & Chairman of the Board.

Are RNAC insiders buying or selling?

Recent insider activity shows net buying of $72.40M.